SEC Form 4 · accession 0001104659-15-062782
POZEN INC /NC · POZN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John R Plachetka
10% Owner
Period of report
Aug 27, 2015
Accepted (ET)
Aug 31, 2015 · 5:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001059790
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $8.83 | Aug 27, 2015 | M | 154,486 | D | — | — | Common Stock | 154,486 | 154,486 | D |
Explanation of responses
- F1The Option shall become exercisable as follows: (a) 100% of the Option will become exercisable upon FDA Approval of YOSPRALA(TM) ("FDA Approval") by December 31, 2015; (b) 75% of the Option shall become exercisable upon FDA Approval between January 1, 2016 and March 31, 2016 with 25% of the Option automatically terminating on January 1, 2016 without ever becoming exercisable; or (c) 50% of the Option shall become exercisable upon FDA Approval between April 1, 2016 and June 30, 2016 with the remaining 25% of the Option automatically terminating on April 1, 2016 without ever becoming exercisable.
- F2The Option shall terminate on August 27, 2025, or, if FDA Approval is not received by June 30, 2016, the Option shall expire without ever becoming exercisable at 5:00 p.m. EDT on June 30, 2016.